20:00 , Jul 13, 2018 |  BC Week In Review  |  Company News

Novartis returns rights for Aveo's preclinical cachexia program

Novartis AG (NYSE:NVS; SIX:NOVN) will return to Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) rights for AV-380 and other related growth differentiation factor 15 (GDF15) inhibitor antibodies, according to an SEC filing. Aveo granted Novartis exclusive, worldwide rights to...
20:12 , Jul 3, 2018 |  BC Extra  |  Company News

Novartis returns rights for Aveo's preclinical cachexia program

Novartis AG (SIX:NOVN; NYSE:NVS) will return to Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) rights for AV-380 and other related growth differentiation factor 15 (GDF15) inhibitor antibodies, according to an SEC filing. Aveo granted Novartis exclusive, worldwide rights to...
03:08 , Dec 14, 2017 |  BC Innovations  |  Translation in Brief

Ghrelin’s LEAP forward

NGM and MedImmune researchers have discovered a liver peptide, LEAP2, that is a natural antagonist of the metabolic target ghrelin. The peptide could serve as a new handle for either boosting or dampening ghrelin signaling...
19:21 , Oct 18, 2017 |  BC Extra  |  Preclinical News

Amgen team describes GDF15's role in obesity

In a paper published Wednesday in Science Translational Medicine, researchers from Amgen Inc. (NASDAQ:AMGN) showed the involvement of growth differentiation factor 15 (GDF15) in regulating body weight in mice, rats, and non-human primates. Amgen is the...
20:42 , Oct 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Patient sample, cell culture and mouse studies suggest inhibiting GDF15 could help treat pancreatic ductal adenocarcinoma (PDAC). In patients, plasma and tumor levels of GDF15 were higher than in samples from healthy volunteers,...
19:43 , Oct 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Obesity; cachexia Mouse and rat studies suggest GDF15 could help treat obesity, and inhibiting its receptor GFRAL could help treat cachexia. In a mouse model of high-fat diet-induced obesity and a genetic rat model of...
23:12 , Oct 2, 2017 |  BC Extra  |  Preclinical News

NGM targeting GFRAL for both obesity and cachexia

NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) plans to develop separate candidates modulating GDNF family receptor alpha like (GFRAL) to treat both obesity and cachexia. In a newly published paper, an NGM team showed GFRAL...
19:58 , Sep 21, 2017 |  BC Innovations  |  Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race is...
17:08 , Sep 13, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Obesity Mouse, rat and non-human primate studies suggest GDF15 could help treat obesity. In mouse models of high-fat diet-induced obesity, intraperitoneal or subcutaneous injection of GDF15 decreased food intake, body weight, and blood glucose levels...
17:33 , Aug 28, 2017 |  BC Extra  |  Preclinical News

Teams identify GFRAL as target for obesity

In three separate papers published in Nature Medicine on Monday, researchers at Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO), Eli Lilly and Co. (NYSE:LLY) and the Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ)...